Growth hormone treatment in Noonan syndrome: report of four cases who reached final height
Related Experiment Videos
G Municchi1, A M Pasquino, I Pucarelli
1Pediatric Department, University La Sapienza, Rome, Italy.
Hormone Research
|January 1, 1995
Abstract:
Final height of 4 patients with Noonan syndrome and short stature treated with growth hormone (GH) is reported. Four prepubertal girls (chronological age 12.3-15.1 years, bone age 11.0-11.5 years) were treated with recombinant human growth hormone (0.5 IU/kg/week s.c.) for at least 3 years. Stimulated GH secretion was normal, spontaneous nocturnal GH secretion was low in 1 patient. Final height, as standard deviation score according to Ranke-specific standards for Noonan syndrome, improved in 3 patients and 2 of the exceeded their corrected midparental height.